Fulltext

Open-Label Study of Absorption and Clearance of 1% Voriconazole Eye Drops

Neoh CF 1 , Leung L 2 , Chan E 3 , Al-Badriyeh D 4 , Fullinfaw RO 5 , Jhanji V 3 Show all authors , Vajpayee RB 3 , Davies GE 2 , Stewart K 6 , Kong DC 7

Affiliations 

  • 1 Collaborative Drug Discovery Research (CDDR) Group, Faculty of Pharmacy, Universiti Teknologi MARA, Puncak Alam, Selangor, Malaysia
  • 2 Department of Pharmacy, Royal Victorian Eye and Ear Hospital (RVEEH), East Melbourne, Victoria, Australia
  • 3 Corneal Unit, Royal Victorian Eye and Ear Hospital (RVEEH), Centre for Eye Research Australia, East Melbourne, Victoria, Australia
  • 4 College of Pharmacy, Qatar University, Doha, Qatar
  • 5 Special Chemistry, Melbourne Health Pathology, The Royal Melbourne Hospital, Parkville, Victoria, Australia
  • 6 Centre for Medicine Use and Safety, Faculty of Pharmacy and Pharmaceutical Sciences, Monash University, Parkville, Victoria, Australia
  • 7 Centre for Medicine Use and Safety, Faculty of Pharmacy and Pharmaceutical Sciences, Monash University, Parkville, Victoria, Australia david.kong@monash.edu
Antimicrob Agents Chemother, 2016 11;60(11):6896-6898.
PMID: 27550348 DOI: 10.1128/AAC.00683-16

Abstract

Twenty participants undergoing elective cataract surgery received 1% voriconazole eye drops (1 drop per eye) either 20, 40, 60, or 80 min before surgery. Median voriconazole concentrations of 1.9 to 3.2 mg/liter in aqueous humor samples were attained over the first 80 min, which were higher than in vitro MIC90 values for typical fungi that cause keratitis.

* Title and MeSH Headings from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

MeSH terms
Similar publications